Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN.
Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN.
Hepatology. 2021 Sep;74(3):1234-1250. doi: 10.1002/hep.31800. Epub 2021 Aug 30.
Chronic alcohol drinking is a major risk factor for alcohol-associated liver disease (ALD). FK506-binding protein 51 (FKBP5), a cochaperone protein, is involved in many key regulatory pathways. It is known to be involved in stress-related disorders, but there are no reports regarding its role in ALD. This present study aimed to examine the molecular mechanism of FKBP5 in ALD.
We found a significant increase in hepatic FKBP5 transcripts and protein expression in patients with ALD and mice fed with chronic-plus-single binge ethanol. Loss of Fkbp5 in mice protected against alcohol-induced hepatic steatosis and inflammation. Transcriptomic analysis revealed a significant reduction of Transcriptional enhancer factor TEF-1 (TEA) domain transcription factor 1 (Tead1) and chemokine (C-X-C motif) ligand 1 (Cxcl1) mRNA in ethanol-fed Fkbp5 mice. Ethanol-induced Fkbp5 expression was secondary to down-regulation of methylation level at its 5' untranslated promoter region. The increase in Fkbp5 expression led to induction in transcription factor TEAD1 through Hippo signaling pathway. Fkbp5 can interact with yes-associated protein (YAP) upstream kinase, mammalian Ste20-like kinase 1 (MST1), affecting its ability to phosphorylate YAP and the inhibitory effect of hepatic YAP phosphorylation by ethanol leading to YAP nuclear translocation and TEAD1 activation. Activation of TEAD1 led to increased expression of its target, CXCL1, a chemokine-mediated neutrophil recruitment, causing hepatic inflammation and neutrophil infiltration in our mouse model.
We identified an FKBP5-YAP-TEAD1-CXCL1 axis in the pathogenesis of ALD. Loss of FKBP5 ameliorates alcohol-induced liver injury through the Hippo pathway and CXCL1 signaling, suggesting its potential role as a target for the treatment of ALD.
慢性饮酒是酒精相关肝病(ALD)的主要危险因素。FK506 结合蛋白 51(FKBP5)是一种伴侣蛋白,参与许多关键的调节途径。已知其与应激相关疾病有关,但尚无关于其在 ALD 中作用的报道。本研究旨在探讨 FKBP5 在 ALD 中的分子机制。
我们发现 ALD 患者和慢性加单次 binge 乙醇喂养的小鼠肝组织中 FKBP5 转录本和蛋白表达显著增加。在小鼠中敲除 Fkbp5 可防止酒精引起的肝脂肪变性和炎症。转录组分析显示,乙醇喂养的 Fkbp5 小鼠中转录增强因子 TEF-1(TEA)结构域转录因子 1(Tead1)和趋化因子(C-X-C 基序)配体 1(Cxcl1)mRNA 显著减少。乙醇诱导的 Fkbp5 表达继发于其 5'非翻译启动子区域甲基化水平的下调。Fkbp5 表达的增加导致 Hippo 信号通路中诱导转录因子 TEAD1。Fkbp5 可以与 yes 相关蛋白(YAP)上游激酶哺乳动物 Ste20 样激酶 1(MST1)相互作用,影响其磷酸化 YAP 的能力,以及乙醇对肝 YAP 磷酸化的抑制作用导致 YAP 核易位和 TEAD1 激活。TEAD1 的激活导致其靶基因 CXCL1 的表达增加,这是一种趋化因子介导的中性粒细胞募集,导致我们的小鼠模型中肝炎症和中性粒细胞浸润。
我们在 ALD 的发病机制中鉴定出 FKBP5-YAP-TEAD1-CXCL1 轴。FKBP5 的缺失通过 Hippo 途径和 CXCL1 信号改善酒精引起的肝损伤,表明其作为治疗 ALD 的潜在靶点的作用。